CN106923334A - A kind of astaxanthin flexible glue capsule formula and preparation method thereof - Google Patents
A kind of astaxanthin flexible glue capsule formula and preparation method thereof Download PDFInfo
- Publication number
- CN106923334A CN106923334A CN201611199643.9A CN201611199643A CN106923334A CN 106923334 A CN106923334 A CN 106923334A CN 201611199643 A CN201611199643 A CN 201611199643A CN 106923334 A CN106923334 A CN 106923334A
- Authority
- CN
- China
- Prior art keywords
- astaxanthin
- group
- capsule
- sample
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013793 astaxanthin Nutrition 0.000 title claims abstract description 100
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 title claims abstract description 89
- 239000001168 astaxanthin Substances 0.000 title claims abstract description 89
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 title claims abstract description 89
- 229940022405 astaxanthin Drugs 0.000 title claims abstract description 89
- 239000007963 capsule composition Substances 0.000 title claims abstract description 13
- 239000003292 glue Substances 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 30
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 29
- 238000007689 inspection Methods 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000002775 capsule Substances 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 239000002253 acid Substances 0.000 claims abstract description 16
- 239000007908 nanoemulsion Substances 0.000 claims abstract description 15
- 108010010803 Gelatin Proteins 0.000 claims abstract description 14
- 239000008273 gelatin Substances 0.000 claims abstract description 14
- 229920000159 gelatin Polymers 0.000 claims abstract description 14
- 235000019322 gelatine Nutrition 0.000 claims abstract description 14
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 14
- 235000011187 glycerol Nutrition 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 239000008213 purified water Substances 0.000 claims abstract description 14
- 238000005516 engineering process Methods 0.000 claims abstract description 9
- 238000001035 drying Methods 0.000 claims abstract description 8
- 238000001914 filtration Methods 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims abstract description 5
- 239000003813 safflower oil Substances 0.000 claims abstract description 5
- 241000168517 Haematococcus lacustris Species 0.000 claims abstract description 4
- 238000004513 sizing Methods 0.000 claims abstract description 4
- 238000003860 storage Methods 0.000 claims abstract description 4
- 239000007901 soft capsule Substances 0.000 claims description 53
- 238000012856 packing Methods 0.000 claims description 11
- 235000019482 Palm oil Nutrition 0.000 claims description 2
- 239000002540 palm oil Substances 0.000 claims description 2
- 230000036039 immunity Effects 0.000 abstract description 9
- 238000004806 packaging method and process Methods 0.000 abstract description 3
- 235000013402 health food Nutrition 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 89
- 241000700159 Rattus Species 0.000 description 83
- 241000699666 Mus <mouse, genus> Species 0.000 description 78
- 238000012360 testing method Methods 0.000 description 55
- 239000013642 negative control Substances 0.000 description 52
- 210000004369 blood Anatomy 0.000 description 51
- 239000008280 blood Substances 0.000 description 51
- 238000002474 experimental method Methods 0.000 description 51
- 230000000694 effects Effects 0.000 description 50
- 241001465754 Metazoa Species 0.000 description 44
- 230000037396 body weight Effects 0.000 description 40
- 210000002966 serum Anatomy 0.000 description 38
- 210000001519 tissue Anatomy 0.000 description 35
- 239000000243 solution Substances 0.000 description 31
- 102000019197 Superoxide Dismutase Human genes 0.000 description 29
- 108010012715 Superoxide dismutase Proteins 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 28
- 210000000952 spleen Anatomy 0.000 description 21
- 238000003304 gavage Methods 0.000 description 20
- 210000003743 erythrocyte Anatomy 0.000 description 19
- 239000007788 liquid Substances 0.000 description 19
- 230000006870 function Effects 0.000 description 15
- 230000002440 hepatic effect Effects 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 15
- 210000000056 organ Anatomy 0.000 description 14
- 239000002285 corn oil Substances 0.000 description 13
- 235000005687 corn oil Nutrition 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 11
- 238000010171 animal model Methods 0.000 description 11
- 150000001514 astaxanthins Chemical class 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- 230000034994 death Effects 0.000 description 11
- 235000013305 food Nutrition 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 230000000242 pagocytic effect Effects 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 241000287828 Gallus gallus Species 0.000 description 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 210000001835 viscera Anatomy 0.000 description 8
- 102000006587 Glutathione peroxidase Human genes 0.000 description 7
- 108700016172 Glutathione peroxidases Proteins 0.000 description 7
- 230000003064 anti-oxidating effect Effects 0.000 description 7
- 210000003024 peritoneal macrophage Anatomy 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 235000019082 Osmanthus Nutrition 0.000 description 6
- 241000333181 Osmanthus Species 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 231100000460 acute oral toxicity Toxicity 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 6
- 230000007815 allergy Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 230000003442 weekly effect Effects 0.000 description 6
- 206010067482 No adverse event Diseases 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 239000003228 hemolysin Substances 0.000 description 5
- -1 lipid peroxide Chemical class 0.000 description 5
- 210000005228 liver tissue Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 108010006464 Hemolysin Proteins Proteins 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- 208000005374 Poisoning Diseases 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 239000000976 ink Substances 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 231100000682 maximum tolerated dose Toxicity 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 231100000572 poisoning Toxicity 0.000 description 4
- 230000000607 poisoning effect Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- CJDPJFRMHVXWPT-UHFFFAOYSA-N barium sulfide Chemical compound [S-2].[Ba+2] CJDPJFRMHVXWPT-UHFFFAOYSA-N 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 231100000527 sperm abnormality Toxicity 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- 150000004359 1,8-dihydroxyanthraquinones Chemical class 0.000 description 1
- YHVQIDWAIRCSOQ-UHFFFAOYSA-N 1-nitrotetrazol-2-ium chloride Chemical compound [Cl-].[O-][N+](=O)N1C=[NH+]N=N1 YHVQIDWAIRCSOQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- CFRFHWQYWJMEJN-UHFFFAOYSA-N 9h-fluoren-2-amine Chemical class C1=CC=C2C3=CC=C(N)C=C3CC2=C1 CFRFHWQYWJMEJN-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- IWDQPCIQCXRBQP-UHFFFAOYSA-M Fenaminosulf Chemical compound [Na+].CN(C)C1=CC=C(N=NS([O-])(=O)=O)C=C1 IWDQPCIQCXRBQP-UHFFFAOYSA-M 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 244000283207 Indigofera tinctoria Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- 240000007509 Phytolacca dioica Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- WJEIYVAPNMUNIU-UHFFFAOYSA-N [Na].OC(O)=O Chemical compound [Na].OC(O)=O WJEIYVAPNMUNIU-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000013536 elastomeric material Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- GKQWYZBANWAFMQ-UHFFFAOYSA-M lithium;2-hydroxypropanoate Chemical compound [Li+].CC(O)C([O-])=O GKQWYZBANWAFMQ-UHFFFAOYSA-M 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 235000020195 rice milk Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100001265 toxicological assessment Toxicity 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of astaxanthin flexible glue capsule formula, its capsule contents composition formula is made up of the following raw material：The 130g of astaxanthin nanoemulsions 110；The 390g of unrighted acid 370；Its capsule skin formula is made up of according to percentage by weight the following raw material：Glycerine 43 47%；Gelatin 17 21%；Its preparation method of purified water 34 38% is：Prepare astaxanthin nanometer：Haematococcus pluvialis are obtained into astaxanthin nanometer after chemical technology is extracted and is emulsified；The astaxanthin nanometer and unrighted acid that will be obtained are well mixed, and obtain solution I；Gelatin, glycerine, purified water are proportionally mixed, and solution II is obtained by colloidal sol and filtering technique treatment；By above-mentioned solution I and solution II by pelleting PROCESS FOR TREATMENT, sizing is sequentially passed through again, is washed ball, drying, is selected storage after ball, packaging, inspection technique, with the health food that astaxanthin nanoemulsions, safflower seed oil, gelatin, glycerine, purified water are made as primary raw material, with strengthen immunity and oxidation-resisting health-care function.
Description
Technical field
The present invention relates to astaxanthin soft capsule preparing technical field, specially a kind of astaxanthin flexible glue capsule formula and its preparation
Method.
Background technology
Astaxanthin also known as astaxanthin, Astaxanthin, are a Carotenoids, are also the superlative degree of carotenogenesis
Other product, in rediance, chemical constitution is similar to beta carotene, and beta carotene, lutein, canthaxanthin, lycopene
Deng the intermediate product for being all carotenogenesis, therefore in nature, astaxanthin has most strong inoxidizability.It is widely present
Content is higher in the feather of living nature, particularly shrimp, crab, fish, frond, yeast and birds, is main in marine organisms body
One of carotenoid.One of astaxanthin antioxidant most strong in the world, the oxygen radical in effective scavenger-cell, enhancing is thin
Born of the same parents' power of regeneration, maintains organism balance and reduces the accumulation of senile cell, cell and DNA health is protected from inside to outside, so as to protect
Shield skin health, promote hair growth, anti-aging, alleviate sports fatigue, invigorate.Since two thousand eight, it is a large amount of both at home and abroad
Research confirms that astaxanthin has stronger antioxidation activity, in enhance immunity, prevention of tumor, angiocardiopathy, diabetes etc.
Chronic disease develops, and the aspect such as anti-aging has positive facilitation, devises a kind of astaxanthin soft capsule and matches somebody with somebody
Side and preparation method thereof is with certain meaning.
The content of the invention
For problem above, the invention provides a kind of astaxanthin flexible glue capsule formula and preparation method thereof, received with astaxanthin
The health food that rice milk liquid, safflower seed oil, gelatin, glycerine, purified water are made for primary raw material, with strengthen immunity and antioxygen
The healthcare function of change.
To achieve the above object, the present invention provides following technical scheme：A kind of astaxanthin flexible glue capsule formula,
Its capsule contents composition formula is made up of the following raw material：
Astaxanthin nanoemulsions 110-130g；
Unrighted acid 370-390g；
Its capsule skin formula is made up of according to percentage by weight the following raw material：
Glycerine 43-47%；
Gelatin 17-21%；
Purified water 34-38%.
Used as a kind of preferred scheme of the present invention, its capsule contents composition formula is made up of the following raw material：
Astaxanthin nanoemulsions 120g；
Unrighted acid 380g；
Its capsule skin formula is made up of according to percentage by weight the following raw material：
Glycerine 45%；
Gelatin 19%；
Purified water 36%.
Used as a kind of preferred scheme of the present invention, the astaxanthin nanoemulsions use astaxanthin nanoemulsions.
Used as a kind of preferred scheme of the present invention, the unrighted acid is using rich in linoleic safflower seed oil, palm fibre
Palmitic acid oil etc..
The other present invention have also been devised a kind of preparation method of astaxanthin soft capsule, comprise the following steps：
(1) astaxanthin nanometer is prepared：Haematococcus pluvialis are obtained into astaxanthin nanometer after chemical technology is extracted and is emulsified；
(2) the astaxanthin nanometer and unrighted acid that will be obtained are well mixed, and obtain solution I；
(3) gelatin, glycerine, purified water are proportionally mixed, and solution is obtained by colloidal sol and filtering technique treatment
II；
(4) by above-mentioned solution I and solution II by pelleting PROCESS FOR TREATMENT, then sequentially pass through sizing, wash ball, drying, select ball,
Be put in storage after packaging, inspection technique.
Used as a kind of preferred scheme of the present invention, technology of the package is divided into inner packing and external packing in the step (4), and
Inner packing technique is first carried out, then carries out external packing technique.
Compared with prior art, the beneficial effects of the invention are as follows：
The design that the present invention passes through elastomeric material so that equipment when in use, can be very good to automatically restore to just
Normal position, can quickly return just in training of hurdling, and reduce time and the energy hurdled and fall down to the ground and prop up to waste, very well
The safety for protecting the trainer that hurdles, can adjust and adapt to different training requirements, be worthy to be popularized.
Specific embodiment
The technical scheme in the embodiment of the present invention will be clearly and completely described below, it is clear that described implementation
Example is only a part of embodiment of the invention, rather than whole embodiments.Based on the embodiment in the present invention, this area is common
The every other embodiment that technical staff is obtained under the premise of creative work is not made, belongs to the model of present invention protection
Enclose.
Embodiment 1：
A kind of astaxanthin flexible glue capsule formula, its capsule contents composition formula is made up of the following raw material：
Astaxanthin nanoemulsions 110g；
Unrighted acid 370g；
Its capsule skin formula is made up of according to percentage by weight the following raw material：
Glycerine 43%；
Gelatin 17%；
Purified water 34%.
The astaxanthin nanoemulsions use astaxanthin nanoemulsions；The unrighted acid is using rich in linoleic
Safflower seed oil, palm oil etc..
Its preparation method comprises the following steps：
(1) astaxanthin nanometer is prepared：Haematococcus pluvialis are obtained into astaxanthin nanometer after chemical technology is extracted and is emulsified；
(2) the astaxanthin nanometer and unrighted acid that will be obtained are well mixed, and obtain solution I；
(3) gelatin, glycerine, purified water are proportionally mixed, and solution is obtained by colloidal sol and filtering technique treatment
II；
(4) by above-mentioned solution I and solution II by pelleting PROCESS FOR TREATMENT, then sequentially pass through sizing, wash ball, drying, select ball,
Be put in storage after packaging, inspection technique.
Technology of the package is divided into inner packing and external packing in the step (4), and first carries out inner packing technique, then carries out outer
Technology of the package.
Embodiment 2：
Difference from Example 1 is：
A kind of astaxanthin flexible glue capsule formula, its capsule contents composition formula is made up of the following raw material：
Astaxanthin nanoemulsions 120g；
Unrighted acid 380g；
Its capsule skin formula is made up of according to percentage by weight the following raw material：
Glycerine 45%；
Gelatin 19%；
Purified water 36%.
Embodiment 3：
Difference from Example 1 is：
A kind of astaxanthin flexible glue capsule formula, its capsule contents composition formula is made up of the following raw material：
Astaxanthin nanoemulsions 130g；
Unrighted acid 390g；
Its capsule skin formula is made up of according to percentage by weight the following raw material：
Glycerine 47%；
Gelatin 21%；
Purified water 38%.
A, the experiment of astaxanthin soft capsule toxicological assessment：
1 material and method
1.1 samples：By the Q brand astaxanthin soft capsules of W companies censorship, specification：0.5g/, batch number：
SZ20140101, puts the shady and cool place of drying and preserves.People orally recommends consumption, and for everyone (adult), 2 times a day, every time 1, adult body
Calculated by 60kg again, it is 16.7mg/kg BW to convert into dosage.Take capsule 's content to be tested, the proportion for measuring content is
0.9。
1.2 experimental animals and environment：SPF grades of healthy Kunming mouse, is bred by Guangxi Medical University's Experimental Animal Center,
Experimental animal production licence number：SCXK (osmanthus) 2009-0002, Quality of Experimental Animals quality certification number：0006676；SPF grades is good for
Health SD kind rats, are bred, experimental animal production licence number by Guangdong Medical Lab Animal Center：SCXK (Guangdong) 2013-
0002, Quality of Experimental Animals quality certification number：44007200011650.Animal Lab. is barrier system, uses credit number：
SYXK (osmanthus) 2011-0005.Zoopery room temperature：22~25 DEG C, relative humidity：55~70%.
1.3 chmice acute Oral toxicities are tested：Using maximum tolerated dose (MTD) test method(s), select 18~22g's of body weight
Kunming mouse 20, male and female half and half.Animal fasting 16 hours, drinking-water is not limited before experiment.Given by the volume of 0.4mL/20g BW
Animal gavage sample once, is calculated by 0.9 proportion, and dosage is 18000mg/kg BW.The poisoning of animal is observed, recorded after gavage
Performance.Weigh weekly once, observe two time-of-weeks, off-test is dissected animal and carries out gross examination of skeletal muscle.Commented by toxicity grading standard
The acute toxicity of valency tested material.
1.4Ames is tested：Using identified satisfactory salmonella typhimurium histidine deficient TA97a,
Tetra- kinds of bacterial strains of TA98, TA100, TA102 are tested.5.0g samples, plus dimethyl sulfoxide (DMSO) are weighed to 100mL, is mixed, be made into
50mg/mL strength solutions, then 5 times of dilutions (taking 10mL plus dimethyl sulfoxide (DMSO) to 50mL) successively, be made into 10 respectively, 2,0.4,
0.08mg/mL strength solutions, test solution is for experiment after being processed through autoclaving (0.103Mpa 20min).Joined with many chlorine
Rat liver microsomes enzyme (the S of benzene induction-9) as Metabolic Activation of Cyclophosphamide.Using flat board incorporation methods, in the top layer training of insulation
0.1mL test strains enrichment liquid, 0.1mL tested materials solution and 0.5mL S are sequentially added in foster base-9Mixed liquor (when need metabolism
During activation), poured into after mixing on bottom culture medium flat plate.5 test doses are respectively 5000,1000,200,40,8 μ g/ wares,
Set simultaneously and beam back certainly change control, solvent control and Positive mutants agent control.Compareed in addition to sample is not added with from beaming back to become, remaining condition
It is identical with sample sets.Solvent control substitutes sample with dimethyl sulfoxide (DMSO), and remaining condition is identical with sample sets.Each dosage group it is each
Plant bacterial strain and make 3 parallel wares.Cultivated 48 hours at 37 DEG C, count the clump count per ware.The whole series experiment is under the same conditions
Repetition is done twice.To increase above and become more than 2 times of clump count from beaming back if the returning of tested material becomes clump count, and with dosage-
Reaction relation person, as mutagenesis testing are positive.
1.5 mouse marrow cell micro nuclear tests：Using interval 24 hours twice oral administration by gavage tested.The body weight is selected to be
The Kunming mouse of 25~30g 50, is randomly divided into 5 groups, every group 10, male and female half and half.3 dosage of test group set respectively
10000th, 5000,2500mg/kg BW, with corn oil as negative control, the endoxan (cp) of 40mg/kg BW dosage makees positive
Control.Weigh 40.0 respectively, 20.0,10.0g samples, respectively with corn oil to 80mL, mix, be made into 500,250,125mg/mL
Strength solution, then gives animal gavage by the volume of 0.4mL/20g BW, and negative control group is filled to isometric corn oil, positive
Control group is filled to isometric 2mg/mL cyclophosphamide solutions.Animal is put to death to 6 hours cervical dislocations after sample second, take breastbone
Marrow dilutes smear with calf serum, and methyl alcohol is fixed, Giemsa dyeing.Under an optical microscope, every animal counts 1000
Polychromatic erythrocyte (PCE), PCE number of the observation containing micronucleus, micronuclear rates is in terms of the PCE permillages containing micronucleus；200 are counted simultaneously
Polychromatic erythrocyte, calculates the ratio (PCE/NCE) of polychromatic erythrocyte and mature erythrocyte.Using in SPSS statistical softwares
Poisson distribution mean comparison method statistical disposition.As the micronuclear rates of test group increases than negative control group, and there is obvious dosage-anti-
Should be related to and statistical significance, as positive findings.
1.6 mouse inbred strains：The Male Kunming strain mice 50 that body weight is 25~35g is selected, 5 groups are randomly divided into,
Every group 10.3 dosage of test group set 10000 respectively, 5000,2500mg/kg BW, with corn oil as negative control, 40mg/
The endoxan (cp) of kg BW dosage makees positive control.Weigh 40.0 respectively, 20.0,10.0g samples, respectively with corn oil extremely
80mL, mix, be made into 500,250,125mg/mL strength solutions, then give animal gavage by the volume of 0.4mL/20g BW, it is cloudy
Property control group is filled to isometric corn oil, and positive controls are filled to isometric 2mg/mL cyclophosphamide solutions.Daily gavage
Once, continuous 5 days.Last put to death animal to the 30th day after sample, took the sperm smear of epididymis, and methyl alcohol is fixed, eosin stains.
Under light microscope, every zoometer counts up to whole sperm 1000, calculates rate of teratosperm.Using in SPSS statistical softwares
Wilcoxon rank test statistical dispositions.Rate of teratosperm such as test group increases than negative control group, has significantly meaning through statistics
Justice, and have dose-response relationship, as positive findings.
1.7 feeding trials of rat 30 days
1.7.1 dosage choice gives mode with tested material：Select SD kinds rat 80, female, male half and half, body weight is 60~
80g.Animal is randomly divided into 4 groups, i.e. negative control group and 3 test groups, every group 20, female, male half and half.3 test group agent
Amount is set to 1670,835,418mg/kg BW, be respectively equivalent to human body and recommend 100,50,25 times of consumption.Weigh respectively
33.40th, 16.70,8.35g samples, respectively with corn oil to 100mL, mix, be made into 334.0,167.0,83.5mg/mL concentration it is molten
Liquid, corresponding dosage group animal gavage is given by the volume of 0.5mL/100g BW, and negative control group is filled to the corn oil of equivalent, daily
Gavage once, continuous gavage 30 days.
1.7.2 experimental technique：All animals give normal diet during experiment, and single cage is raised, drinking-water of freely ingesting.Daily
The activity of observation animal and growing state, add food 2 times weekly, record to appetite and surplus appetite, and a body weight is claimed weekly, calculate every
All food-intakes and food utilization.Experiment terminates animal fasting overnight (fasting 16h does not limit drinking-water), then claims animal empty stomach body
Weight, puts to death rat, adopts 2 parts of blood samples, and a blood anti-freezing detects Hb, RBC, WBC and its classification, PLT etc. with blood counting instrument；Separately
A blood not anti-freezing separates serum, with kit and automatic clinical chemistry analyzer detect serum AST, ALT, BUN, Cr, TC, TG,
The projects such as Glu, TP, Alb.Animal is dissected after blood sampling, gross examination of skeletal muscle is carried out, taking the internal organs such as liver, kidney, spleen and testis is carried out
Weigh, calculate dirty/body ratio, taking the internal organs such as liver, kidney, spleen, Stomach duodenum, testis and ovary carries out pathological tissue
Learn and check.When making gross examination to each dosage group animal and not finding obvious lesion and Biochemical index change, high dose is only carried out
Group and control animals main organs histopathological examination, such as discovery lesion if centering, low dose group corresponding organ and
Tissue is checked.
1.7.3 experimental data is counted：One-way analysis of variance is carried out using SPSS statistical softwares.In statistical analysis, first
Homogeneity test of variance is carried out to data, if variance is neat, overall comparing is carried out using one-way analysis of variance, found differences and use again
Dunnett inspections carry out comparing two-by-two between multiple dosage groups and control group mean.Data are carried out suitably if heterogeneity of variance
Variable conversion, after meeting homogeneity test of variance, counted with the data after conversion；If it is neat that change data is still not up to variance
It is required that, using rank test instead carries out statistical analysis.
2 results
2.1 acute oral toxicity tests
The acute toxicity tests of the Q brand astaxanthin soft capsules of table 1 to mouse
As seen from Table 1, after giving mouse stomach with the sample of 18000mg/kg BW dosage, growth of animal is good, has no body
It is affected again.Test mice is showed no poisoning symptom, observes 14 days without animal dead.Animal, substantially is dissected in off-test
The main organs such as observation, liver,kidney,spleen, the heart, lung, stomach, intestines are showed no obvious abnormalities change.Result shows that the sample is to mouse
Acute oral toxicity MTD is more than 18000mg/kg BW, and acute oral toxicity belongs to nontoxic level.
2.2Ames is tested
The Q brand astaxanthin soft capsule first time Salmonella reversion test results of table 2
Note：1st, result above (clump count) is 3 means standard deviations of plate.
2nd, positive control：TA97a+S9, TA98+S9, TA100+S9 use 2- aminofluorenes (dosage is 10 μ g/ wares)；TA98
- S9 uses daunomycin (dosage is 6 μ g/ wares)；TA97a-S9, TA102-S9 use fenaminosulf (dosage is 50 μ g/ wares)；
TA100-S9 uses Sodium azide (dosage is 1.5 μ g/ wares)；TA102+S9 uses 1,8- dihydroxy anthraquinones, and (dosage is 50 μ g/
Ware).Table 3 is same.
From table 2, table 3, to tetra- kinds of test strains of TA97a, TA98, TA100, TA102, regardless of whether adding S-9, sample
Returning for each dosage group of product becomes clump count not less than the twice for beaming back change clump count certainly, also without dose-response relationship, shows that this is received
Examination thing mutagenesis testing result is feminine gender.
Note：Result above (clump count) is 3 means standard deviations of plate.
Influence of the sesame Yong board natural astaxanthin soft capsule of table 4 to the bone marrow cell micronucleus incidence of mouse
Note：* compares with negative control group, P ＜ 0.01；Cp is endoxan.
As seen from Table 4, the bone marrow cell micronucleus rate of each dosage group mouse of sample compares with negative control group, and difference is without aobvious
Work property (P ＞ 0.05), in range of normal value, each dosage group PCE/NCE values are no less than feminine gender to the PCE/NCE values of each dosage
The 20% of control group, compares also no significant difference with negative control group, and the micronuclear rates of endoxan positive controls with it is negative
The difference of control group has very significant (P ＜ 0.01), points out to have no that the sample has the bone marrow cell of mouse damage and suppresses
Effect.
Influence of the Q brand astaxanthin soft capsules of table 5 to Sperm Abnormalities of Mice
Note：* compares with negative control group, P ＜ 0.01；Cp is endoxan.
As seen from Table 5, sample does not produce substantially change to Sperm Abnormalities of Mice, and the sperm of each dosage group of sample is abnormal
Form quotient compares with negative control group, and there are no significant for difference (P ＞ 0.05), and endoxan positive controls and negative control group
Difference have very significant (P ＜ 0.01), point out the sample not produce distortion to act on the sperm of male mice.
2.5 feeding trials of rat 30 days
2.5.1 animal typically shows：During experiment, each group animal growth is good, have no animal have abnormal behaviour and
Poisoning manifestations, each group animal is without death
2.5.2 influence of the sample to rat body weight and food utilization
The results are shown in Table 6~table 11, with 1670,835, the Q brand astaxanthin soft capsules of 418mg/kg BW dosage fill to rat
Stomach 30 days, during experiment, each dosage group male and female mouse of sample body weight weekly, gain in weight, weekly food-intake and total food-intake, weekly
Food utilization and total foodstuff utilization rate compare with control group, and there are no significant for difference (P ＞ 0.05), shows the sample to rat
Body weight increase and food utilization have no significant effect.
Influence of the Q brand astaxanthin soft capsules of table 6 to rat body weight
Note：Each dosage group compares with negative control group in table, and there are no significant for difference (P ＞ 0.05).
Influence of the Q brand astaxanthin soft capsules of table 7 to the 1st week body weight increase of rat and food utilization
Note：Each dosage group compares with negative control group in table, and there are no significant for difference (P ＞ 0.05).
Influence of the Q brand astaxanthin soft capsules of table 8 to the 2nd week body weight increase of rat and food utilization
Note：Each dosage group compares with negative control group in table, and there are no significant for difference (P ＞ 0.05).
Influence of the Q brand astaxanthin soft capsules of table 9 to the 3rd week body weight increase of rat and food utilization
Note：Each dosage group compares with negative control group in table, and there are no significant for difference (P ＞ 0.05).
Influence of the Q brand astaxanthin soft capsules of table 10 to the 4th week body weight increase of rat and food utilization
Note：The number of days of the 4th week is 9 days.Each dosage group compares with negative control group in table, there are no significant for difference (P ＞
0.05)。
Influence of the Q brand astaxanthin soft capsules of table 11 to rat total foodstuff utilization rate
Note：Each dosage group compares with negative control group in table, and there are no significant for difference (P ＞ 0.05).
2.5.3 influence of the sample to rat routine blood indexes
The 30 days feeding trials of Q brand astaxanthins soft capsule of table 12 terminate rat routine blood indexes inspection result
Note：Each dosage group compares with negative control group in table, and there are no significant for difference (P ＞ 0.05).
The 30 days feeding trials of Q brand astaxanthins soft capsule of table 13 terminate rat routine blood indexes inspection result
Note：Each dosage group compares with negative control group in table, and there are no significant for difference (P ＞ 0.05).
From table 12, table 13, with 1670,835, the Q brand astaxanthin soft capsules of 418mg/kg BW dosage fill to rat
Stomach 30 days, each dosage group of sample is female, male rat hemoglobin, Erythrocytes, total white blood cells and its classification, blood platelet
Number compares with control group, and there are no significant for difference (P ＞ 0.05), shows the sample to the routine blood indexes of rat without obvious shadow
Ring.
2.5.4 influence of the sample to rat blood biochemical indicator
The results are shown in Table 14, table 15, with 1670,835, the Q brand astaxanthin soft capsules of 418mg/kg BW dosage fill to rat
Stomach 30 days, each dosage group of sample is female, male rat serum glutamic oxalacetic transaminase, glutamic-pyruvic transaminase, urea nitrogen, creatinine, cholesterol,
Triglycerides, total protein, albumin, blood sugar compare with control group, and there are no significant for difference (P ＞ 0.05), shows the sample pair
The blood parameters of rat have no significant effect.
The 30 days feeding trials of Q brand astaxanthins soft capsule of table 14 terminate rat blood biochemical indicator inspection result
Note：Each dosage group compares with negative control group in table, and there are no significant for difference (P ＞ 0.05).
The 30 days feeding trials of Q brand astaxanthins soft capsule of table 15 terminate rat blood biochemical indicator inspection result
Note：Each dosage group compares with negative control group in table, and there are no significant for difference (P ＞ 0.05).
2.5.5 influence of the sample to Rats Organs and Tissues weight and internal organs/body weight ratio
The results are shown in Table 16, table 17, with 1670,835, the Q brand astaxanthin soft capsules of 418mg/kg BW dosage fill to rat
Stomach 30 days, the liver,kidney,spleen of each dosage group rat of sample, male mouse testicular weight and liver/body, kidney/body, spleen/body, male mouse testis/body
Ratio compares with control group, and there are no significant for difference (P ＞ 0.05), shows the sample to the organ weights of rat and internal organs/body
Anharmonic ratio value has no significant effect.
Influence of the Q brand astaxanthin soft capsules of table 16 to Rats Organs and Tissues weight
Note：Each dosage group compares with negative control group in table, and there are no significant for difference (P ＞ 0.05).
Influence of the Q brand astaxanthin soft capsules of table 17 to Rats Organs and Tissues/body weight ratio
Note：Each dosage group compares with negative control group in table, and there are no significant for difference (P ＞ 0.05).
2.5.6 gross examination of skeletal muscle and histological indications are dissected
Experiment terminates to dissect animal, and gross examination of skeletal muscle each group animal does not find obvious lesion.Therefore the only high dose of sampling product
The main organs of group and negative control group animal carry out tissue pathological slice inspection, the results are shown in Table 18~table 24.Result shows, high
Dosage group has 1 male and 2 females, the control groups to have the visible slight liver of the lobuli hepatis tissue of 2 males and 2 female rats
Cellular fat is denatured, and high dose group has 1 male, control group to have the visible liver of lobuli hepatis of 1 male and 1 female rats thin
Born of the same parents' spotty necrosis, high dose group and control group have the liver portal area of 1 male and 1 female rats visible a small amount of scorching thin
Born of the same parents infiltrate；High dose group has 1 male and 1 female, the control group to have between 1 male and 2 Renal Cortex portions of female rats
The visible a small amount of cell infiltration of matter.Above lesion tissue belongs to the spontaneous light-duty lesion of animal, and two groups of lesion tissue journeys of animal
Degree is similar, therefore caused by can excluding and being sample, other organs tissue has no that Histopathology changes, and shows the sample to rat
The above-mentioned harmless effect of organs and tissues.
Table 18 Q brand astaxanthins soft capsule, 30 days feeding trial rat liver tissue pathological examination results
The Q brand astaxanthins 30 days feeding trial rat kidney of soft capsule of table 19 carefully knit pathological examination result
Table 20 Q brand astaxanthins soft capsule, 30 days feeding trial Rats Spleen histopathological examination results
Table 21 Q brand astaxanthins soft capsule, 30 days feeding trial rat stomach histopathological examination results
Table 22 Q brand astaxanthins soft capsule, 30 days feeding trial rat preduodenal histopathological examination results
23 Q brand astaxanthins soft capsule of table, 30 days feeding trial rat hero mouse testis tissue pathological examination results
24 Q brand astaxanthins soft capsule of table, 30 days feeding trial rat raettin ovary tissue pathological examination results
3 brief summaries
After giving mouse stomach with the sample of 18000mg/kg BW dosage, have no that animal has poisoning symptom and death, the sample
Product are more than 18000mg/kg BW to the acute oral toxicity MTD of mouse, and acute oral toxicity belongs to nontoxic level.Three genetoxics
Experiment (Salmonella reversion test, mouse marrow cell micro nuclear test, mouse inbred strain) result is feminine gender.Feed examination within 30 days
Test, with 1670,835, the sample of 418mg/kg BW (be respectively equivalent to human body and recommend 100,50,25 times of consumption) 3 dosage connects
Continue to rat oral gavage 30 days, animal growth is good during experiment, body weight, gain in weight, food-intake, the food of each dosage group rat
Thing utilization rate, routine blood indexes, blood parameters, organ weights and internal organs/body weight ratio etc. compares with control group, without aobvious
Write sex differernce (P>0.05)；Gross anatomy observation and histopathological examination have no the abnormal change relevant with sample.Tested
Have no that the sample produces toxic and side effect to rat items observation index in dosage range.
B, Q brand astaxanthin soft capsule anti-oxidation function Report on Animal
1 material and method
1.1 samples：By the Q brand astaxanthin soft capsules of W companies censorship, specification：0.5g/, batch number：
SZ20140101, puts the shady and cool place of drying and preserves.People orally recommends consumption, and for everyone (adult), 2 times a day, every time 1, adult body
Calculated by 60kg again, it is 16.7mg/kg BW to convert into dosage.Capsule 's content is taken to be tested.
1.2 experimental animals and environment：From SPF grades of 10 monthly age above SD of Guangxi Medical University's Experimental Animal Center breeding
Plant male rat 40,591.1 ± 26.6g of body weight, experimental animal production licence number：SCXK (osmanthus) 2009-0002, experiment is dynamic
Amount of substance quality certification number：0006243.Animal Lab. is barrier system, uses credit number：SYXK (osmanthus) 2011-0005.
Zoopery room temperature：22~25 DEG C, relative humidity：55~75%.
1.3 dosage choices give mode with tested material：Human body recommended amounts according to sample set 334,167,84mg/kg BW
(being respectively equivalent to 20,10,5 times that human body recommends consumption) 3 dosage groups, while setting a negative control group, every group 10 are moved
Thing.Take submitted sample 6.68,3.34,1.68g respectively, respectively with corn oil to 100mL, mix, be made into 66.8,33.4,
The solution of 16.8mg/mL concentration, using oral mode, gives corresponding dosage group animal gavage respectively, and gavage volume is 0.5mL/
100g BW, negative control group gives isometric corn oil, daily gavage once, continuous gavage 30 days.
1.4 instruments and reagent
1.4.1 instrument：Hitachi KY2000 types semi-automatic biochemical analyzer, electronic analytical balance, refrigerated centrifuge, thermostatted water
Bath cabinet, swirl mixing device etc..
1.4.2 reagent：Physiological saline, MDA, protein carbonyl group, (bio-engineering research is built up in Nanjing to SOD, GSH kit
There is provided) etc..
1.5 experimental techniques：According to state's food medicine prison guarantorization [2012] 107 of State Food and Drug Administration's issue
《On printing and distributing 9 notices of healthcare function evaluation method such as anti-oxidation function evaluation method》1-anti-oxidation function of annex comment
Valency method.Tested old rats feed observation 7 days in SPF grades of zoopery room, and the intraocular corner of the eyes takes hematometry blood after no abnormality seen
Clear MDA (MDA) content.Rat stratified random is divided into by 4 groups according to MDA contents, every group 10, and suitably adjust, make
The average weight of each group is also balanced as far as possible.By the volume of 0.5mL/100g BW, each dosage group animal gavage phase is given respectively
Answer the sample solution of concentration, negative control group gives isometric corn oil, daily gavage once, continuous gavage 30 days, then
Animal is put to death, taking blood, hepatic tissue carries out observation index measure.
1.5.1 LPO assays in rat blood serum and liver tissue homogenate's liquid (with MDA content meters).
1.5.2 protein oxidation products (protein carbonyl group) assay in rat blood serum and liver tissue homogenate's liquid.
1.5.3 antioxidase (SOD) vitality test in rat blood serum and liver tissue homogenate's liquid.
1.5.4 polyphenoils (GSH) assay in rat blood serum and liver tissue homogenate's liquid.
1.6 experimental datas are counted：Experimental data carries out statistical disposition with variance analysis.
1.7 result judgements：LPO, protein carbonyl group, activities of antioxidant enzymes, polyphenoils four indices
In three index positives, can determine that the anti-oxidant results of animal of the given the test agent is positive.
2 result of the tests
Influence of 2.1 samples to rat body weight
The body weight no significant difference of each group rat before experiment, process of the test and terminate each dosage group of sample rat body weight and
Gain in weight compares with negative control group, difference there are no significant (P>0.05), show the sample to the body weight of old rats without bright
Development rings, and is shown in Table 1.
The changes of weight of each group rat during the experiment of table 1
Note：The body weight and gain in weight of each period each group rat compare in table, and there are no significant for difference (P ＞ 0.05).
Note：The body weight and gain in weight of each period each group rat compare in table, difference there are no significant (P>0.05).
Influence of 2.2 samples to rat blood serum and tissue lipid peroxide (LPO) content
The Serum LPO content of each group animal is more balanced before experiment, no significant difference (P between each group>0.05).Experiment is eventually
End, the serum of each dosage group rat of sample and lipid peroxide (LPO) content of hepatic tissue are below negative control group, but each dose
Amount group compares with control group, no significant difference (P>0.05) 2, are shown in Table, show serum and tissue of the sample to old rats
LPO is acted on without obvious reduction.
The serum and hepatic tissue lipid peroxide (LPO is in terms of MDA) content of each group rat of table 2
Influence of 2.3 samples to rat blood serum and tissue protein carbonyl content
The serum and hepatic tissue content of protein carbonyl group of each group rat of table 3
Experiment is last eventually, and the serum of each dosage group rat of sample and the content of protein carbonyl group of hepatic tissue are below negative control
Group, wherein the difference of high, middle dose group serum proteins carbonyl content and negative control group has pole conspicuousness (P ＜ 0.01),
3 are shown in Table, show that the sample has the effect for reducing old rats Proteins in Serum carbonyl content.
Influence of 2.4 samples to superoxide dismutase (SOD) vigor in rat blood serum and tissue
Experiment is last eventually, and SOD vigor is above negative control group in the serum and hepatic tissue of each dosage group rat of sample, wherein
High dose group serum and hepatic tissue SOD vigor have conspicuousness (P ＜ 0.01 or P ＜ 0.05) with the difference of negative control group, are shown in Table
4, show the sample can improve old rats serum and hepatic tissue in superoxide dismutase (SOD) activity.
Serum and hepatic tissue the SOD activity of each group rat of table 4
Influence of 2.5 samples to rat blood serum and tissue GSH-PX activity (GSH) content
Experiment is last eventually, and GSH contents are above negative control group in the serum and hepatic tissue of each dosage group rat of sample, wherein
High dose group hepatic tissue GSH contents have conspicuousness (P with the difference of negative control group<0.05) 5, are shown in Table, show the sample energy
Enough improve glutathione (GSH) content in old rats hepatic tissue.
The serum and hepatic tissue GSH contents of each group rat of table 5
3 brief summaries
Respectively with 334,167, the Q product of 84mg/kg BW dosage (being respectively equivalent to 20,10,5 times that human body recommends consumption)
Board astaxanthin soft capsule gives old rats continuous gavage 30 days, can reduce the content of the Proteins in Serum carbonyl of rat,
The activity of superoxide dismutase (SOD) in the serum and hepatic tissue of rat is improved, the hepatic tissue GSH-PX activity of rat is improved
(GSH) content, the body weight to rat has no significant effect, and shows that the sample has anti-oxidation function.
C, Q brand astaxanthin soft capsule anti-oxidation function-human feeding trial report
1 material and method
1.6 samples：By the Q brand astaxanthin soft capsules of W companies censorship, specification is 0.5g/, batch number：
SZ20140101, puts the shady and cool place of drying and preserves.Human body recommends consumption, and for everyone (adult), 2 times a day, 1 every time.
1.7 study subjects
1.2.1 subject's inclusive criteria：Age, physical condition was good at 40~65 years old, without obvious brain, the heart, liver,
Lung, kidney, Hematological Diseases, without Long-term taking medicine history, volunteer tested and ensure cooperation person.This experiment is initial to be had 120 and meets and receive
Enter condition person's aspiration and participate in experiment.
1.2.2 Subject Exclusion Criteria：(1) gestation or women breast-feeding their children and to this product allergy sufferers；(2) merge intentionally, brain
The serious diseases such as blood vessel, liver, kidney and hemopoietic system and mental patient；(3) article relevant with tested function is taken in a short time,
Have influence on the judgement person to result；(4) inclusive criteria is not met, not by the edible given the test agent of regulation, it is impossible to judge effect or money
Umbra does not ring effect or security judgement person to material.
3 experimental designs and packet：Using itself and between group two kinds of control designs.Contained with subject's blood MDA (MDA)
Based on amount, take into account superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activity is layered, Ran Housui
Machine is divided into test-meal group and control group, every group of each 60 people；Principal element such as age, sex, the life of influence result are considered as far as possible
Eating habit etc., carries out harmonious inspection, to ensure the comparativity between group.
4 edible dosage and times：Everyone takes 2 times test-meal group test-meal sample daily, 1 every time, continuously takes 3 months,
Control group uses blank.Two groups of primary work of crowd, eating habits are constant during experiment.
5 key instruments and reagent：Electrocardiogram, X-ray examination machine, B ultrasonic scanner, Biochemical Analyzer, blood counting instrument, blood pressure
Meter etc..MDA, SOD, GSH-PX determine kit and build up Bioengineering Research Institute's production by Nanjing.
6 observation index
1.6.1 safety indexes
2.6 ordinary circumstances：Including mental status, sleep, diet, stool and urine etc., recorded by subject daily.
2.7 blood routine examinations：Using full-automatic blood counting instrument detect routine blood indexes, before experiment, experiment end respectively test one
It is secondary.
2.8 stool, urine routine inspections：Before experiment, test each inspection in end once.
2.9 blood pressures and Liver and kidney function inspection：Taken blood pressure with blood pressure measuring, blood is determined using automatic clinical chemistry analyzer
Main Liver and kidney function index, before experiment, tests each survey in end once.
2.10 Chest X-rays, electrocardiogram, Abdominal B type ultrasonography：Fluoroscopy of chest, electrocardiogram and an Abdominal B type ultrasonography are carried out before on-test
Check.Before experiment, test each survey in end once.
1.6.2 efficiency index
1.6.2.1 LPO：The change of MDA and MDA decline percentage before and after viewing test.
1.6.2.2 superoxide dismutase activity：The change of SOD and SOD rise high percent before and after viewing test.
1.6.2.3 activity of glutathione peroxidase：GSH-P before and after viewing testXChange and GSH-PXRaise percentage
Rate.
1.7 test data statistical dispositions：Own control data uses paired t-test, two groups of means to compare using the inspections of t in groups
Test.Percentage χ2Inspection is tested.On the premise of comparing difference is without conspicuousness between two groups before the test, after being tested
Compare between two groups.
1.8 result judgements：Itself compare before and after each functional observation index Test and test-meal after compare between group and there is statistics to anticipate
Justice, can judge that the index is positive.
Appoint in LPO, superoxide dismutase activity, three indexs of activity of glutathione peroxidase
Two experimental result positives, can determine that the given the test agent has anti-oxidation function.
2 results
2.1 ordinary circumstances：7 lost to follow-up in experiment, rate lost to follow-up is 5.8%, final control group and test-meal group distinguish 56 and
57 entrance are effectively counted.Before test-meal, age, mental status, sleep quality, diet situation of test-meal group and control group crowd etc.
It is basically identical；Two groups of fluoroscopies of chest of crowd, electrocardiogram and Abdominal B type ultrasonography inspection results are showed no obvious abnormalities.Two groups before test-meal
The blood LPO of crowd, superoxide dismutase activity and activity of glutathione peroxidase ratio
Compared with without notable difference (P>0.05), it is shown in Table 1.
Two groups of crowd's basic conditions before the test-meal of table 1
Influence of 2.2 samples to blood LPO
Two groups of blood lipid peroxide (MDA) content no significant difference (P of crowd before test-meal>0.05).After test-meal, test-meal
The MDA contents of group are less than control group, and difference has conspicuousness (P<0.01)；The MDA contents of test-meal group averagely decline 14.96%, greatly
In the 0.77% of control group, difference has conspicuousness (P<0.01)；Also there be significantly itself comparing difference before and after the MDA experiments of test-meal group
Property (P<0.01), front and rear itself comparing difference of control group is then without conspicuousness (P>0.05) 2, are shown in Table,
Show that the sample has the effect of the blood LPO for reducing examination trencherman.
Two groups of blood LPO changes of crowd before and after the test-meal of table 2
Influence of 2.3 samples to Blood Superoxide Dismutase (SOD) activity
The two groups of Blood Superoxide Dismutase of crowd (SOD) activity no significant difference (P before test-meal>0.05).After test-meal,
The blood SOD activity of test-meal group crowd is average to raise 12.24%, and more than the 0.16% of control group, difference has conspicuousness (P ＜
0.01)；Itself comparing difference also has itself ratio before and after conspicuousness (P ＜ 0.01), control group before and after the blood SOD experiments of test-meal group
Compared with difference then without conspicuousness (P ＞ 0.05), 3 are shown in Table, show that the sample has and raise examination trencherman's blood SOD
The effect of activity.
Two groups of blood superoxide dismutase changes of crowd before and after the test-meal of table 3
Influence of 2.4 samples to blood glutathione peroxidase (GSH-Px) activity
Two groups of blood glutathione peroxidase (GSH-Px) content no significant difference (P ＞ of crowd before test-meal
0.05).After test-meal, apparently higher than control group, difference has conspicuousness (P ＜ 0.05) to the GSH-Px activity of test-meal group；Test-meal group
GSH-Px activity is average to raise 10.89%, and more than the 0.14% of control group, difference has conspicuousness (P ＜ 0.01)；Test-meal group
Comparing difference also has conspicuousness (P ＜ 0.01) before and after GSH-Px itself, and control group itself comparing difference is then without conspicuousness (P ＞
0.05) 4, are shown in Table, show that the sample has the effect for raising examination trencherman's blood GSH-Px activity.
Two groups of blood glutathione peroxidase activity changes of crowd before and after the test-meal of table 4
Influence of 2.5 samples to safety indexes
Table 5 tests front and rear two groups of crowd's blood pressures, the measurement result of heart rate
Before and after test-meal, two groups of blood pressures of crowd, hearts rate before and after normal range (NR), test-meal group blood pressure, the test-meal of heart rate from
Compare before and after body and test-meal after group between compare, difference there are no significant difference (P ＞ 0.05) shows the sample to subject's
Blood pressure and heart rate have no adverse effects, and are shown in Table 5.
2.5.2 the sample influence conventional to urine, feces the results are shown in Table 6 and table 7, before and after test-meal, test-meal group and control group crowd
Urine acid-base value, transparency, color and urinary sediment microscopy be showed no exception, albumen is feminine gender.Two groups of stool colour, property
Shape and microscopy are showed no exception, show that the sample routinely has no adverse effects to the stool, urine of subject.
Table 6 tests the assay of front and rear two groups of crowd's routine urinalysis
Table 7 tests the assay of front and rear two crowds stool routine examination
2.5.3 before and after influence test-meal of the sample to blood routine, erythrocyte number, the leucocyte of test-meal group and control group crowd
Number and content of hemoglobin are just
In the range of constant value, 8 are shown in Table, show that the sample has no adverse effects to the blood routine of subject.
Table 8 tests the assay of front and rear two groups of crowd's blood routines
2.5.4 influence of the sample to blood biochemical functional parameter
Table 9 tests the assay of front and rear two groups of crowd's blood parameters
As seen from Table 9, before and after test-meal, two groups of hepatic and renal function hematological indices inspection results of crowd are in range of normal value
It is interior, show that the sample has no adverse effects to the Liver and kidney function of subject.
2.5.5 two groups of volunteers do not occur nausea, flatulence, diarrhoea and allergy etc. in the adverse reaction process of the test of sample
Adverse reaction.
3 brief summaries
1.4 (the control groups 56 of volunteer 113 for meeting the tested inclusion criteria of this experiment：Man 29, female 27；Test-meal
Group 57：Man 27, female 30).Wherein test-meal group crowd continuously took Q brand astaxanthin soft capsules after 3 months, blood MDA
Content averagely declines 14.96%, noticeably greater than 0.77% (P ＜ 0.01) of control group, compares before and after test-meal group itself and test-meal
Comparing difference has conspicuousness (P ＜ 0.01) between the group of control group afterwards；SOD activity is average in test-meal group crowd's blood raises
Comparing difference has conspicuousness (P ＜ before and after 12.24%, noticeably greater than 0.16% (P ＜ 0.01) of control group, test-meal group itself
0.01)；Test-meal group crowd's blood GSH-Px activity is average to raise 10.89%, is significantly higher than 0.14% (P ＜ of control group
0.01), compare before and after test-meal group itself and test-meal after between the group of control group comparing difference have conspicuousness (P ＜ 0.01 and P ＜
0.05) also there is significant difference (P ＜ 0.05)；And MDA, SOD and GSH-Px of control group crowd, itself is more equal before and after experiment
There is no significant difference (P ＞ 0.05).Judge accordingly, the sample has anti-oxidation function.Before and after experiment, test-meal sample sets crowd
Erythrocyte number, leukocyte count, hemoglobin, stool and urine routine, total serum protein, albumin, glutamic-oxalacetic transaminease, Gu Bingzhuan
The items inspection result such as ammonia enzyme, urea nitrogen, creatinine, blood sugar shows in range of normal value, and before and after experiment without significant change
The sample has no adverse effects to subject's health.
D, Q brand astaxanthin soft capsule strengthen immunity functional experiment are reported
1 material and method
1.4.1 sample：By the Q brand astaxanthin soft capsules of W companies censorship, specification：0.5g/, batch number：
SZ20140101, puts the shady and cool place of drying and preserves.People orally recommends consumption, and for everyone (adult), 2 times a day, every time 1, adult body
Calculated by 60kg again, it is 16.7mg/kg BW to convert into dosage.
1.4.2 experimental animal and packet：SPF grades of healthy Male Kunming strain mice 240, body weight is 18~22 grams, by wide
Western medical university's Experimental Animal Center breeding, experimental animal production licence number：SCXK (osmanthus) 2009-0002, experimental animal matter
Amount quality certification number：0006739.Every 40 mouse are one group, totally 6 groups.Immune I groups, the mice spleen lymph for carrying out ConA inductions is thin
Born of the same parents' transformation experiment；It is immune II group, carry out delayed allergy experiment；It is immune III group, dirty/body ratio measurement is carried out, serum is molten
Sanguinin is determined and antibody-producting cell number is determined；It is immune IV~VI group, carbonic clearance experiment, peritoneal macrophage phagocytosis are carried out respectively
Chicken red blood cell is tested and NK cytoactive detections.
1.4.3 experimental animal room environmental condition：Animal Lab. is barrier system, uses credit number：SYXK (osmanthus)
2011-0005.Zoopery room temperature：22~25 DEG C, relative humidity：55~70%.
1.4.4 dosage choice gives mode with tested material：Consumption is orally recommended according to people, if the basic, normal, high dosage group of sample
Respectively 84,167,334mg/kg BW (be respectively equivalent to human body and recommend 5,10,20 times of consumption), if a negative control group,
Every group of 10 animals.Sample contents 0.84,1.67,3.34g are weighed respectively, respectively with corn oil to 200mL, mixed, be made into
4.20th, 8.35,16.70mg/mL strength solutions, corresponding dosage group animal gavage is given by the volume of 0.2mL/10g BW, negative
Control group gives isometric corn oil, daily gavage once, continuous gavage 30~35 days.
1.4.5 key instrument and reagent：Animal balance, electronic analytical balance, centrifuge, clean bench, carbon dioxide
Incubator, constant water bath box, microscope, semi-automatic biochemical analyzer, ELIASA etc..
Sterile surgical instrument, micro syringe, cell counter, the flat Tissue Culture Plate in 24 holes and 96 holes, 96 holes are U-shaped
Tissue Culture Plate, glass dish, gauze, slide, test tube, 200 eye mesh screens, timer, hemoglobin pipet etc..
RPMI1640 nutrient solutions, calf serum, 2-ME, penicillin, streptomysin, the HCL solution of ConA, 1mol/L, isopropyl
Alcohol, MTT, Hank ' s liquid (pH 7.2~7.4), PBS (Ph7.2~7.4), platform phenol indigo plant, DNFB, acetone, barium sulphide, benefit
Body (GPS), SA buffer solutions, agarose, sheep red blood cell (SRBC) (SRBC), physiological saline, india ink, 0.1% carbonic acid
Sodium, chicken red blood cell, methyl alcohol, Gimsa dye liquors, YAC-1 cells, lithium lactate, nitro tetrazolium chloride, PMS,
NAD, the Tris-HCL buffer solutions of 0.2mol/L, 1% glacial acetic acid, 1% NP40 etc..
1.4.6 experimental technique
Internal organs/body weight ratio measurement：Mouse is put to death after weighing, thymus gland and spleen is taken out, weighed on electronic analytical balance,
Calculate dirty/body ratio.
The mouse spleen lymphocyte transformation experiment (mtt assay) of ConA inductions is aseptic to take spleen, be placed in fill it is appropriate aseptic
In the plate of Hank ' s liquid, cell suspension is made, through 200 mesh sieve net filtrations.Washed 2 times with Hank ' s liquid, 10min is centrifuged every time
(1000r/min).Then cell is suspended in 1mL complete culture solutions, living cell counting number, is adjusted with RPMI1640 nutrient solutions
Whole cell concentration is 3 × 106Individual/mL.During cell suspension point holes added into 24 well culture plates again, per hole 1mL, wherein one
Hole adds 75 μ L ConA liquid (equivalent to 7.5 μ g/mL), and 5%CO is put in another hole as control2, trained in 37 DEG C of carbon dioxide incubators
Support 72h.Culture terminates preceding 4h, and supernatant 0.7mL is gently sucked per hole, adds RPMI1640s of the 0.7mL without calf serum to train
Nutrient solution, while adding MTT (5mg/mL) 50 μ L/ holes, continues to cultivate 4h.After culture terminates, 1mL acid isopropyl alcohol is added per hole,
Piping and druming is mixed, and is completely dissolved purple crystal.Then it is dispensed into 96 well culture plates, 3 parallel holes are made in each hole, use enzyme mark
Instrument, OD value is determined with 570nm wavelength.The multiplication capacity use of lymphocyte plus the OD value in ConA holes are subtracted and are not added with ConA
The OD value in hole is represented.
1.6.3 the mouse DTH of dinitrofluorobenzene induction tests (ear swelling method)
Experiment terminates first 5 days with barium sulphide by mouse part skin depilation about 3cm × 3cm scopes, with 50 μ L DNFB solution
Uniform application sensitization, is attacked 10 μ L DNFB uniform applications in mouse right ear two sides after 5 days, cervical dislocation after 24 hours
Mouse is put to death, left and right auricular concha is cut, the auricle of 8mm diameters is removed with card punch, is weighed, represented with the difference of left and right ear weight
The degree of DTH.
1.6.4 antibody-producting cell detection (Jerne improves slide methods)
The sheep blood of de- fiber is taken, with brine 3 times, 10min (2000r/min) is centrifuged every time, use physiological saline
Hematocrit SRBC is made into the cell suspension of 2% (v/v), per mouse intraperitoneal injection 0.2mL.The sacrifice of 5 days, takes after will be immune
Spleen is put in the plate for filling Hank ' s liquid, gently grinds spleen, is made cell suspension, through 200 mesh sieve net filtrations, centrifugation
10min (1000r/min), is washed 2 times with Hank ' s liquid, and finally cell is suspended in 5mL RPMI1640 nutrient solutions.By table
After layer culture medium (1g agaroses add distilled water to 100mL) heating for dissolving, put 45~50 DEG C of water-baths insulation, with equivalent Ph7.2~
7.4th, Hank ' the s liquid mixing of 2 times of concentration, dispenses small test tube, often pipe 0.5mL, then to added in pipe 50 μ L10%SRBC (v/v,
Use SA buffers), 25 μ L splenocyte suspensions, it is rapid mix after be poured on the slide of brush agarose thin layer, do parallel
Piece, after after agar solidification, the flat button of slide is placed in glass frame, is put into CO2gas incubator and is incubated 1.5h, is buffered with SA
The complement (1 of liquid dilution:8) add in glass frame groove, continue to be incubated 1.5h, count hemolysis plaque number.With plaque number/106Spleen
Cell represents antibody-producting cell number.
1.6.5 the measure (Hemagglutination Method) of serum hemolysin
The sheep blood of de- fiber is taken, with brine 3 times, 10min (2000r/min) is centrifuged every time, use physiological saline
Hematocrit SRBC is made into the cell suspension of 2% (v/v), per mouse intraperitoneal injection 0.2mL.After immune 5 days, the eyeball of mouse is extractd,
Blood is taken in about 1h, 2000r/min centrifugation 10min in centrifuge tube, is placed, separated, collected serum.With physiological saline by serum multiple proportions
Dilution, the serum of different dilution factors is respectively placed in Microhemagglutination plate, per the μ L of hole 100, adds 100 μ L 0.5% (v/v)
SRBC suspensions, mix, added a cover in the square position for loading moistening, in 37 DEG C of incubation 3h, observe hemagglutination degree.As the following formula
Calculating antibody product：
Antibody product=(S1+2S2+3S3……nSn)
1,2,3 ... n are the index of two-fold dilution in formula, and S is the rank of aggegation degree.1.6.6 mouse carbonic clearance experiment
Through tail vein to the india ink of 4 times of mouse injection normal saline dilution, 0.1 mL, ink are injected per 10g body weight
Timing immediately after juice injection, the 2nd, 10min after prepared Chinese ink is injected takes the μ L of blood 20 from angular vein clump respectively, is added to 2mL
0.1%Na2CO3In solution, shake up.With Na2CO3Solution makees blank, with 600nm wavelength densitometrics value (OD).By mouse
Put to death, take liver, spleen, weigh.It is calculated as follows phagocytic index a.
A=K1/3K=(lgOD in × body weight/(liver weight+spleen weight) formula1- lgOD2)/(t2-t1)
1.6.7 Turnover of Mouse Peritoneal Macrophages phagocytosis chicken red blood cell tests (half intracorporal method)
To the hematocrit chicken erythrocyte suspension of mouse peritoneal injection 20% (v/v, with normal saline), per mouse 1mL, interval
30min, cervical dislocation puts to death mouse, and abdominal skin is cut off in center, and Intraperitoneal injection 2mL physiological saline rotates mouse plate 1min, suctions out
Abdominal cavity washing lotion 1mL, mean droplet is put into the enamel box for being lined with wet gauze on 2 slides, is put 37 DEG C of incubators and is incubated 30min.
Incubate complete, take out after slide is rinsed in physiological saline and dry, use methyl alcohol:Acetone (1:1) solution is fixed, 4% (v/v) Giemsa-
Phosphate buffer is dyeed, then is rinsed with pure water, dried.100 macrophages of every counting, are calculated as follows phagocytic rate under oil mirror
And phagocytic index.
Number of macrophages × 100 phagocytic index of the number of macrophages/counting of phagocytic rate (%)=phagocytosis chicken red blood cell=
The number of macrophages of the chicken red blood cell sum/counting for being swallowed
1.6.8NK cytoactive detection (LDH determination methods)
Mouse cervical dislocation is put to death, it is aseptic to take spleen, splenocyte suspension is made, washed 2 times with Hank ' s liquid, every time centrifugation
10min(1000r/min).Supernatant is abandoned, cytoplasm is upspring, add 0.5mL sterilizings pure water 20 seconds, added after splitting erythrocyte
2 times of Hank ' s liquid of 0.5mL and 8mL Hank ' s liquid, 1000r/min centrifugation 10min, 10 % calf serums are contained with 1mL
RPMI1640 complete culture solutions are resuspended, and (viable count should be more than 95%) is counted after being diluted with 1% glacial acetic acid, contaminated with platform phenol is blue
Color living cell counting number, it is 2 × 10 finally to adjust cell concentration with RPMI1640 complete culture solutions7Individual/mL, this is that effect is thin
Born of the same parents.The well-grown YAC-1 cells of 24h after passage are taken, it is 4 × 10 to adjust cell concentration with RPMI1640 complete culture solutions5Individual/
ML, this is target cell.Take target cell and each 100 μ L of effector cell (are imitated target and compare 50:1), in U-shaped 96 well culture plate of addition；Target is thin
Born of the same parents' Spontaneous release hole adds target cell and each 100 μ L of nutrient solution, and target cell maximum release aperture adds target cell and each 100 μ L of 1%NP40.
Above-mentioned items respectively set 3 parallel holes, to put and cultivate 4h in 5%CO2,37 DEG C of carbon dioxide incubators.Then by 96 well culture plates with
1500r/min is centrifuged 5min, per hole in the well culture plate of 100 μ L horizontalizations bottom of absorption supernatant 96, while adding the μ of LDH matrix liquids 100
L, is reacted 8 minutes, and the HCL30 μ L of 1mol/L are added per hole, and optical density (OD) value is determined at ELIASA 490nm.Count as the following formula
Calculate NK cytoactives.
NK cytoactives (%)=(reacting hole OD- Spontaneous releases hole OD)/(maximum release aperture OD- Spontaneous releases hole
OD) × 100%
Experimental data is counted：Variance analysis statistical disposition is carried out using SPSS statistical softwares.
1.5.5 result judgement：Lived in cellular immune function, humoral immune function, monocytes/macrophages function, NK cells
Property four aspects any two aspect results it is positive, can determine that the given the test agent has strengthen immunity function.
2 results
Influence of 1.8 samples to Mouse Weight
The Q brand astaxanthin soft capsule strengthen immunity functional experiment Mouse Weights of table 1
The Q brand astaxanthin soft capsule strengthen immunity functional experiment Mouse Weights of table 2
Note：The mouse of immune II~VI each dosage groups of group is initial, mid-term and latter stage body weight and weightening and negative control group ratio
Compared with there are no significant for difference (P ＞ 0.05).
From table 1, table 2, experiment is first, test mid-term and experiment latter stage, the Mouse Weight of each dosage group of sample and experiment
The body weight increase of period mouse compares between negative control group, and there are no significant for difference (P ＞ 0.05), shows the sample to mouse
Body weight increase have no significant effect.
Influence of 2.2 samples to mouse immune organ internal organs/body weight ratio
Immune organ internal organs/body weight the ratio of the Q brand astaxanthin soft capsule strengthen immunity functional experiment mouse of table 3
From table 3, the mouse thymus/body weight and spleen of each dosage group of sample/body weight ratio compare with negative control group,
Difference that there are no significant (P ＞ 0.05), shows that the sample has no significant effect to the immune organ weight of mouse.
Influence of 2.3 samples to the cellular immunity of mouse
The influence of the mouse spleen lymphocyte conversion capability that 2.4 samples are induced ConA
The mouse spleen lymphocyte transformation experiment result of the Q brand astaxanthin soft capsules of table 4
As seen from Table 4, the mouse spleen lymphocyte conversion capability of each dosage group of sample is higher than negative control group, and high dose
Group has conspicuousness (P ＜ 0.05) with the difference of negative control group, shows that there is the sample SPL for promoting mouse to increase
Grow, the effect of conversion capability.
2.3.2 influence of the sample to mouse delayed allergy (DTH)
Mouse delayed allergy (DTH) experimental result of the Q brand astaxanthin soft capsules of table 5
As seen from Table 5, mouse of each dosage group of sample or so auricle weight difference is higher than negative control group, and high dose group
There is conspicuousness (P ＜ 0.05) with the difference of negative control group, show that the sample has the delayed allergy for promoting mouse
Effect.
Influence of 2.4 samples to the humoral immunity of mouse
2.4.1 influence of the sample to the antibody-producting cell number of mouse
The mouse antibodies cellulation test experience result of the Q brand astaxanthin soft capsules of table 6
As seen from Table 6, the mouse hemolysis plaque number of each dosage group of sample is higher than negative control group, and high dose group and feminine gender
The difference of control group has conspicuousness (P ＜ 0.05), shows that the sample has the work of the antibody-producting cell propagation for promoting mouse
With.
2.4.2 influence of the sample to mice serum hemolysin
The mouse hemolysin test experimental result of the Q brand astaxanthin soft capsules of table 7
As seen from Table 7, the mouse antibodies product of each dosage group of sample is higher than negative control group, and high, middle dose group and the moon
Property control group difference there is conspicuousness (P ＜ 0.01 or P ＜ 0.05), show the sample have improve mouse serum hemolysin
The effect of level.
Influence of 2.5 samples to the monocytes/macrophages phagocytic function of mouse
2.5.1 influence of the sample to the monocytes/macrophages carbonic clearance of mouse
Mouse monokaryon-macrophage carbonic clearance the experimental result of the Q brand astaxanthin soft capsules of table 8
As seen from Table 8, the mouse phagocytic index of each dosage group of sample is higher than negative control group, and high dose group is right with feminine gender
There is conspicuousness (P ＜ 0.05) according to the difference of group, show that the sample has the monocytes/macrophages carbonic clearance function of promoting mouse
Effect.
2.5.2 sample swallows the influence of chicken red blood cell ability to the peritoneal macrophage of mouse
The Turnover of Mouse Peritoneal Macrophages phagocytosis chicken red blood cell experimental result of the Q brand astaxanthin soft capsules of table 9
As seen from Table 9, phagocytic rate and phagocytic index of the Turnover of Mouse Peritoneal Macrophages of each dosage group of sample to chicken red blood cell
Higher than negative control group, but the difference of each dosage group and negative control group there are no significant (P ＞ 0.05), show the sample without bright
The effect of the peritoneal macrophage phagocytic activity of aobvious promotion mouse.
Influence of 2.6 samples to the NK cytoactives of mouse
The NK cells in mice determination of activity result of the Q brand astaxanthin soft capsules of table 10
As seen from Table 10, the NK cells in mice activity of each dosage group of sample is approached with negative control group, each dosage group with it is cloudy
Property control group difference there are no significant (P ＞ 0.05), show that the sample promotes to make to the NK cytoactives of mouse without obvious
With.
3 brief summaries
Orally administration mouse 84,167, the Q brands of 334mg/kg BW (equivalent to 5,10,20 times of human body recommended amounts) dosage
Astaxanthin soft capsule 30~35 days, (spleen lymphocyte proliferation, conversion and delayed are abnormal anti-to promote the cellular immunity of mouse
Should), humoral immunity (antibody-producting cell breed and serum hemolysin), promote the monocytes/macrophages carbonic clearance of mouse
Function, body weight increase, thymus gland to mouse/body weight ratio, spleen/body weight ratio, the phagocytic activity and NK of peritoneal macrophage
Cytoactive has no significant effect, and points out the sample to have strengthen immunity function.
Presently preferred embodiments of the present invention is the foregoing is only, is not intended to limit the invention, it is all in essence of the invention
Any modification, equivalent and improvement made within god and principle etc., should be included within the scope of the present invention.
Claims (6)
1. a kind of astaxanthin flexible glue capsule formula, it is characterised in that：
Its capsule contents composition formula is made up of the following raw material：
Astaxanthin nanoemulsions 110-130g；
Unrighted acid 370-390g；
Its capsule skin formula is made up of according to percentage by weight the following raw material：
Glycerine 43-47%；
Gelatin 17-21%；
Purified water 34-38%.
2. a kind of astaxanthin flexible glue capsule formula according to claim 1, it is characterised in that：
Its capsule contents composition formula is made up of the following raw material：
Astaxanthin nanoemulsions 120g；
Unrighted acid 380g；
Its capsule skin formula is made up of according to percentage by weight the following raw material：
Glycerine 45%；
Gelatin 19%；
Purified water 36%.
3. a kind of astaxanthin flexible glue capsule formula according to claim 1, it is characterised in that：The astaxanthin nanoemulsions are adopted
Use astaxanthin nanoemulsions.
4. a kind of astaxanthin flexible glue capsule formula according to claim 1, it is characterised in that：The unrighted acid is used
Rich in linoleic safflower seed oil, palm oil etc..
5. a kind of preparation method of astaxanthin soft capsule, it is characterised in that comprise the following steps：
(1) astaxanthin nanometer is prepared：Haematococcus pluvialis are obtained into astaxanthin nanometer after chemical technology is extracted and is emulsified；
(2) the astaxanthin nanometer and unrighted acid that will be obtained are well mixed, and obtain solution I；
(3) gelatin, glycerine, purified water are proportionally mixed, and solution II is obtained by colloidal sol and filtering technique treatment；
(4) by above-mentioned solution I and solution II by pelleting PROCESS FOR TREATMENT, then sizing is sequentially passed through, ball, drying is washed, is selected ball, bag
Be put in storage after dress, inspection technique.
6. the preparation method of a kind of astaxanthin soft capsule according to claim 5, it is characterised in that in the step (4)
Technology of the package is divided into inner packing and external packing, and first carries out inner packing technique, then carries out external packing technique.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611199643.9A CN106923334A (en) | 2016-12-22 | 2016-12-22 | A kind of astaxanthin flexible glue capsule formula and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611199643.9A CN106923334A (en) | 2016-12-22 | 2016-12-22 | A kind of astaxanthin flexible glue capsule formula and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106923334A true CN106923334A (en) | 2017-07-07 |
Family
ID=59443962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611199643.9A Pending CN106923334A (en) | 2016-12-22 | 2016-12-22 | A kind of astaxanthin flexible glue capsule formula and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106923334A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109349553A (en) * | 2018-11-29 | 2019-02-19 | 徐州市迪港商贸有限公司 | A kind of astaxanthin flexible glue capsule formula |
| CN109480285A (en) * | 2018-12-10 | 2019-03-19 | 丽江程海湖天然螺旋藻生产基地有限公司 | A kind of haematococcus pluvialis soft capsule |
| CN111567805A (en) * | 2020-06-16 | 2020-08-25 | 云南爱尔康生物技术有限公司 | Water-soluble haematococcus pluvialis astaxanthin soft capsule and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008179619A (en) * | 2006-12-28 | 2008-08-07 | Nisshin Pharma Inc | Astaxanthin containing composition |
| CN103719301A (en) * | 2013-12-24 | 2014-04-16 | 青岛银色世纪健康产业集团有限公司 | Healthy food taking astaxanthin oil as main material |
| CN104042568A (en) * | 2014-06-23 | 2014-09-17 | 青岛优度生物工程有限公司 | Astaxanthin nanoemulsion preparation and preparation method thereof |
| CN104257632A (en) * | 2014-10-24 | 2015-01-07 | 北京化工大学 | Solid lipid nanometer particle for astaxanthin and preparation method of solid lipid nanometer particle |
| CN104705654A (en) * | 2015-04-02 | 2015-06-17 | 徐权汉 | Preparation method for astaxanthin microcapsules |
| CN105055482A (en) * | 2015-09-14 | 2015-11-18 | 王衍斌 | Nutritional supplement and preparation method of soft capsule thereof |
-
2016
- 2016-12-22 CN CN201611199643.9A patent/CN106923334A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008179619A (en) * | 2006-12-28 | 2008-08-07 | Nisshin Pharma Inc | Astaxanthin containing composition |
| CN103719301A (en) * | 2013-12-24 | 2014-04-16 | 青岛银色世纪健康产业集团有限公司 | Healthy food taking astaxanthin oil as main material |
| CN104042568A (en) * | 2014-06-23 | 2014-09-17 | 青岛优度生物工程有限公司 | Astaxanthin nanoemulsion preparation and preparation method thereof |
| CN104257632A (en) * | 2014-10-24 | 2015-01-07 | 北京化工大学 | Solid lipid nanometer particle for astaxanthin and preparation method of solid lipid nanometer particle |
| CN104705654A (en) * | 2015-04-02 | 2015-06-17 | 徐权汉 | Preparation method for astaxanthin microcapsules |
| CN105055482A (en) * | 2015-09-14 | 2015-11-18 | 王衍斌 | Nutritional supplement and preparation method of soft capsule thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109349553A (en) * | 2018-11-29 | 2019-02-19 | 徐州市迪港商贸有限公司 | A kind of astaxanthin flexible glue capsule formula |
| CN109480285A (en) * | 2018-12-10 | 2019-03-19 | 丽江程海湖天然螺旋藻生产基地有限公司 | A kind of haematococcus pluvialis soft capsule |
| CN111567805A (en) * | 2020-06-16 | 2020-08-25 | 云南爱尔康生物技术有限公司 | Water-soluble haematococcus pluvialis astaxanthin soft capsule and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101978841B (en) | Protein allergy-resisting and nutritious infant formula milk powder | |
| CN101606706A (en) | A kind of health food of compound bee product raw material | |
| CN107348483A (en) | A kind of pregnant and lying-in women's full function nutritious supplementary pharmaceutical | |
| CN101422239A (en) | Combined partner capable of increasing edible rice, flour nutrition | |
| CN103300446A (en) | Functional blueberry beverage composition | |
| CN102344500A (en) | Prepared polygonum multiflorum polysaccharide and application thereof in preparing anti-aging medicament | |
| CN106923334A (en) | A kind of astaxanthin flexible glue capsule formula and preparation method thereof | |
| CN104938684A (en) | Tea for assisting reduction of blood lipid and preparation method thereof | |
| CN104667197B (en) | A kind of composition of strengthen immunity and its preparation method and application | |
| CN104012982B (en) | A kind of preparation method with the soft capsule that strengthens immunity function | |
| CN102860496B (en) | Oxidation-resisting health-care food for improving immunity and preparation method thereof | |
| CN103421720A (en) | Complex microbial inoculant for broiler chickens and application thereof to improvement of broiler chicken productivity and immunity | |
| CN106138440B (en) | A kind of composition containing maca and root of kirilow rhodiola and preparation method and purposes | |
| CN103690573B (en) | A kind of natural drug composition for strengthen immunity and preparation method thereof | |
| CN107802695A (en) | A kind of health composition of the strengthen immunity containing saline cistanche and preparation method thereof | |
| CN108669555A (en) | A kind of Algal Assemblages object, preparation, preparation method and applications | |
| CN107951992A (en) | A kind of Chinese medicine composition for strengthen immunity and preparation method thereof | |
| CN102920847B (en) | Composition for strengthening immunity and preparation and application thereof | |
| CN101317605B (en) | Novel formulating method for functional milk powder | |
| CN105249465A (en) | Health food capable of improving immunity and preparation method of health food | |
| CN102406172B (en) | Health-care food for enhancing immunity and preparation method thereof | |
| CN101015345A (en) | Health-care food with hypoxia-resistant and immunity-enhancing functions and its preparing process | |
| CN108713738A (en) | A kind of American Ginseng siberian solomonseal rhizome composition, preparation method, preparation and application | |
| CN104489692A (en) | Health food with natural source resveratrol and making method thereof | |
| CN108142926A (en) | Lotus wheat drinks health care particle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170707 |